S214: PHASE 1/2 STUDY OF ANBAL-CEL, NOVEL ANTI-CD19 CAR-T THERAPY WITH DUAL SILENCING OF PD-1 AND TIGIT IN RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA

• W. S. Kim,
• S. J. Kim,
• S. E. Yoon,
• J. R. Kim

Affiliations

W. S. Kim

1 Hematology and Oncology, Samsung Medical Center, Seoul

S. J. Kim

1 Hematology and Oncology, Samsung Medical Center, Seoul

S. E. Yoon

1 Hematology and Oncology, Samsung Medical Center, Seoul

J. R. Kim

2 Clinical Development, Curocell Therapeutics, DaeJeon, South Korea